Celldex Therapeutics, Inc. (NASDAQ:CLDX) had its target price trimmed by Jefferies Group LLC from $5.00 to $4.00 in a research report released on Wednesday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Celldex Therapeutics from a hold rating to a buy rating and set a $5.00 target price on the stock in a report on Thursday, November 17th. HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Celldex Therapeutics in a report on Wednesday, March 15th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $7.63.

Celldex Therapeutics (NASDAQ:CLDX) opened at 3.37 on Wednesday. The firm has a 50-day moving average price of $3.43 and a 200-day moving average price of $3.66. Celldex Therapeutics has a one year low of $2.85 and a one year high of $5.13. The firm’s market capitalization is $415.23 million.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.04. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The company had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.10 million. During the same quarter last year, the company earned ($0.33) earnings per share. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts expect that Celldex Therapeutics will post ($1.23) EPS for the current year.

Your IP Address:

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacad Investment Ltd. bought a new position in Celldex Therapeutics during the fourth quarter worth $146,000. Virginia Retirement Systems ET AL bought a new position in Celldex Therapeutics during the third quarter worth $150,000. Tudor Investment Corp Et Al raised its position in Celldex Therapeutics by 256.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 47,806 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 34,400 shares in the last quarter. Creative Planning raised its position in Celldex Therapeutics by 971.4% in the third quarter. Creative Planning now owns 55,346 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 50,180 shares in the last quarter. Finally, Paulson & CO. Inc. bought a new position in Celldex Therapeutics during the fourth quarter worth $251,000. Institutional investors own 55.99% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

5 Day Chart for NASDAQ:CLDX

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.